Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations

Discontinued Operations

3 Months Ended

Mar. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

11.

DISCONTINUED OPERATIONS

The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included Income (Loss) from Discontinued Operations, Net of Tax in the consolidated statements of comprehensive income (loss) for the three-months ended March 31, 2017 and 2016.

	Three Months Ending March 31,
	2017		2016
Revenue, net	$	-	$	1,644

Income (loss) from discontinued operations, before tax		610		(735	)
Income tax expense		54		45
Income (loss) from discontinued operations, net of tax	$	556	$	(780	)

The assets and liabilities classified as discontinued operations relate to CSO, Group DCA, Pharmakon, and TVG. As of March 31, 2017 and December 31, 2016, these assets and liabilities are in the accompanying balance sheets as follows:

	For the Three Months Ended						For the Year Ended
	March 31, 2017						December 31, 2016
	CSO		DCA/TVG		Total		CSO		DCA/TVG		Total
Accounts receivable. net	$	-	$	-	$	-	$	-	$	-	$	-
Unbilled receivable. net		-		-		-		-		-		-
Other		-		-		-		-		14		14
Current assets from discontinued operations		-		-		-		-		14		14
Property and equipment. net		-		-		-		-		-		-
Other		-		-		-		-		-		-
Long-term assets from discontinued operations		-		-		-		-		-		-
Total assets	$	-	$	-	$	-	$	-	$	14	$	14

Accounts payable	$	868	$	-	$	868	$	890	$	-	$	890
Accrued salary and bonus		51		-		51		1.272		-		1.272
Other		1,827		-		1,827		1,966		-		1,966
Current liabilities from discontinued operations		2,746		-		2,746		4,128		-		4,128
Total liabilities	$	2,746	$	-	$	2,746	$	4,128	$	-	$	4,128